financetom
Business
financetom
/
Business
/
'Semicaps' Applied Materials, KLA, Lam Research Could Benefit From Emergence of DeepSeek, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
'Semicaps' Applied Materials, KLA, Lam Research Could Benefit From Emergence of DeepSeek, Oppenheimer Says
Jan 27, 2025 9:04 AM

11:42 AM EST, 01/27/2025 (MT Newswires) -- Semiconductor capital equipment companies, or semicaps, such as Applied Materials ( AMAT ) , KLA (KLAC), and Lam Research ( LRCX ) , could benefit from the emergence of Chinese artificial-intelligence startup DeepSeek, Oppenheimer said Monday.

"We see Deepseek as counterintuitively a long-term demand positive for semicaps," the firm said in a note, noting that the open-source Chinese AI model will spur a reduction in the cost of artificial intelligence adoption at the large language model and application layers.

Deepseek is outperforming Microsoft ( MSFT )-backed (MSFT) OpenAI's model at a much lower cost, Oppenheimer said.

"Semicaps remain agnostic, supplying critical tools to all players, ensuring they benefit from the broader AI expansion," the firm said. The emergence of Deepseek is also seen "expanding the pool of economical buyers at the infrastructure layer beyond megacap hyperscalers," while accelerating competitive pressures in generative AI, thus driving increased investment, Oppenheimer said.

Shares of Applied Materials ( AMAT ) were down 7.5% in recent trading amid the broader tech selloff in the wake of the launch of the DeepSeek AI assistant. KLA fell more than 6%, while Lam Research ( LRCX ) shed nearly 6%. Microsoft ( MSFT ) shares were down almost 4%.

Price: 427.89, Change: -16.17, Percent Change: -3.64

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Airbus faces new output pressure amid parts shortages, sources say
Airbus faces new output pressure amid parts shortages, sources say
May 31, 2024
PARIS, May 31 (Reuters) - Airbus is facing new pressure on its near-term production ramp-up for passenger jets due to parts and labour shortages, industry sources said on Thursday. It was not immediately clear whether the slowdown would put at risk delivery targets for 2024 since deliveries lag output decisions by several months, but the sources said assembly of several...
Update: Marvell Technology's Shares Decline Pre-Bell After Fiscal Q1 Adjusted Earnings, Revenue Decline
Update: Marvell Technology's Shares Decline Pre-Bell After Fiscal Q1 Adjusted Earnings, Revenue Decline
May 31, 2024
05:22 AM EDT, 05/31/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Marvell Technology's ( MRVL ) shares were down more than 4% in premarket activity Friday after the company reported overnight a decline in fiscal Q1 earnings and sales. The company reported fiscal Q1 adjusted earnings late Thursday of $0.24 per diluted...
Update: Dell Technologies Fiscal Q1 Non-GAAP Earnings Fall More Than Forecast While Sales Increase; Shares Sink Premarket
Update: Dell Technologies Fiscal Q1 Non-GAAP Earnings Fall More Than Forecast While Sales Increase; Shares Sink Premarket
May 31, 2024
05:20 AM EDT, 05/31/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Dell Technologies ( DELL ) shares were down 14% in premarket activity Friday after the company reported overnight a steeper-than-anticipated decline in fiscal Q1 earnings. The company reported fiscal Q1 non-GAAP earnings late Thursday of $1.27 per diluted share, down from...
Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US
Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US
May 31, 2024
05:12 AM EDT, 05/31/2024 (MT Newswires) -- Vanda Pharmaceuticals ( VNDA ) said late Thursday it is now allowed to commercialize Ponvory, or ponesimod, in the US. The company said the move follows the transfer of ownership of the US new drug application and investigational new drug applications of ponesimod to the company from a Johnson & Johnson company. Ponvory...
Copyright 2023-2026 - www.financetom.com All Rights Reserved